Medicinal Genomics
Daniel Walsh has an extensive work experience in sales and management roles. Daniel currently holds the position of Vice President of Sales at Medicinal Genomics since December 2022. Prior to this, from June 2019 to December 2022, they served as the Director of Sales CENTOGENE at CENTOGENE AG. Before that, from September 2017 to June 2019, they were the General Manager, North America at Centogene and Centogene US, LLC. Prior to joining Centogene, they worked as the Vice President of Sales at Courtagen Life Sciences, Inc. from May 2012 to September 2017. Daniel started their career at Lincoln Financial Distributors as a Regional Marketing Director from May 2006 to April 2010.
Daniel Walsh attended the University of Notre Dame from 1984 to 1988, where they obtained a Bachelor's degree in Business/Government International Relations.
This person is not in any offices
Medicinal Genomics
Medicinal Genomics is pioneering the genomics of medical cannabis and hemp. In 2011, Medicinal Genomics made worldwide headlines for being the first group to decode the Cannabis Genome. An increasing amount of scientific evidence supports the theory that cannabinoid compounds may have numerous medical benefits. Medicinal Genomics has the largestDNA sequence database of the cannabis plant and is well-positioned to design fingerprinting assays for strain genotyping and sequencing services for strain development. In 2011, Medicinal Genomics was acquired by Courtagen Life Sciences, Inc.